Article
Extended Data Fig. 1 | Age and BMI cohort distributions and Select
Medications distributions. a, b, Aggregated ages (a) and BMIs (b) were
collected for patients with moderate, severe, and fatal COVID-19 and relative
frequency histograms generated for comparison across disease sub-groups.
Gaussian and lognormal distributions were fit through least squares
regression and compared for goodness of fit through differential Akaike
information criterion (AICc) comparison. All distributions were best described
by a Gaussian model except for age in the ‛severe’ disease category, which was
best modelled by a lognormal distribution. c, Proportion of patients admitted
to YNHH receiving hydroxycholorquine (HCQ), tocilizumab (Toci),
methylprednisolone (Solu-medrol), and remdesivir (Rem) are shown, stratified
by disease severity. d, Medication and age adjustments for IL-6 and T cell count.